Walleye Trading LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 143 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2019. The put-call ratio across all filers is 2.57 and the average weighting 0.4%.

Quarter-by-quarter ownership
Walleye Trading LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2024$1,619,035
-35.2%
23,639
-34.5%
0.00%
-40.0%
Q1 2024$2,497,636
+907.6%
36,093
+942.8%
0.01%
+400.0%
Q4 2023$247,877
-65.9%
3,461
-75.2%
0.00%0.0%
Q3 2023$727,072
-81.1%
13,958
-80.3%
0.00%
-87.5%
Q1 2023$3,840,210
+2.3%
70,918
-0.1%
0.01%
-27.3%
Q4 2022$3,754,992
-29.7%
70,956
-38.2%
0.01%
-31.2%
Q3 2022$5,338,000
+270.4%
114,734
+354.6%
0.02%
+220.0%
Q2 2022$1,441,000
-4.9%
25,239
+2.0%
0.01%0.0%
Q1 2022$1,515,000
-8.3%
24,755
-21.7%
0.01%
-16.7%
Q4 2021$1,653,000
+17.7%
31,600
-16.2%
0.01%
+20.0%
Q3 2021$1,405,000
-79.8%
37,700
-77.8%
0.01%
-81.5%
Q2 2021$6,943,000
+1850.3%
170,100
+1520.0%
0.03%
+1250.0%
Q1 2021$356,000
-68.9%
10,500
-70.8%
0.00%
-60.0%
Q4 2020$1,143,000
-30.9%
35,958
-44.2%
0.01%
-37.5%
Q3 2020$1,654,000
+499.3%
64,438
+258.9%
0.01%
+300.0%
Q1 2020$276,000
-98.6%
17,955
-96.8%
0.00%
-98.5%
Q4 2019$19,109,000
+4677.2%
556,960
+941.0%
0.13%
+4300.0%
Q3 2019$400,000
-27.9%
53,500
+25.2%
0.00%
-40.0%
Q2 2019$555,000
-18.5%
42,726
-23.6%
0.01%0.0%
Q1 2019$681,000
+202.7%
55,928
+183.7%
0.01%
+400.0%
Q4 2018$225,000
+11150.0%
19,711
+9755.5%
0.00%
Q2 2017$2,0002000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2019
NameSharesValueWeighting ↓
DCF Advisers, LLC 375,000$15,308,0005.42%
SILVERARC CAPITAL MANAGEMENT, LLC 113,258$4,623,0002.06%
Tri Locum Partners LP 150,783$6,155,0002.02%
COOPER/HAIMS ADVISORS, LLC 61,116$2,495,0001.64%
Vantage Consulting Group Inc 226,670$9,252,0001.61%
Nicholas Investment Partners, LP 598,261$24,421,0001.53%
Bellevue Group AG 3,609,919$147,357,0001.44%
GENERAL AMERICAN INVESTORS CO INC 350,804$14,320,0001.20%
Rhenman & Partners Asset Management AB 429,728$17,541,0001.19%
WASATCH ADVISORS LP 6,506,789$265,607,0001.08%
View complete list of INTRA CELLULAR THERAPIES INC shareholders